Source: Streetwise Reports   05/04/2020

Stemline Therapeutics Inc. (STML:NASDAQ), which is focused on developing and commercializing novel oncology therapeutics, today announced that it has entered into a definitive agreement to be acquired by private Italian pharmaceutical and diagnostics company Menarini Group in a transaction valued up to $677 million.

The companies advised that the transaction has already been unanimously approved by both companies' Boards of Directors and that the transaction is expected to close in Q2/20 subject to customary closing conditions, regulatory approvals and a tender of at least 50% of the outstanding Stemline shares by shareholders. Menarini stated that it plans to fund the purchase by using existing cash resources.

The firms outlined that purchase details and advised that "under the terms of the agreement, a wholly owned subsidiary of the Menarini Group will commence a tender offer for all outstanding shares of Stemline, whereby Stemline shareholders will be offered a total potential consideration of $12.50 per share, consisting of an upfront payment of $11.50 in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 in cash per share upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval."

The report explained that ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123) and was developed by Stemline for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients. The firm stated that the U.S. Food and Drug Administration (FDA) approved that drug in the U.S. in December 2018. A marketing authorization application (MAA) has already been submitted and is presently under review by the European Medicines Agency. Post acquisition, Menarini expects to obtain approvals and expand distribution of ELZONRIS to Europe and emerging markets.

Stemline Therapeutics' Chairman, CEO and Founder Ivan Bergstein, M.D., commented, "Joining Menarini represents a unique opportunity for Stemline to advance the commercialization of ELZONRIS across the globe and to accelerate the development of our pipeline of oncology assets. ...We are excited to be combining with a like-minded organization in Menarini, in a transaction that will deliver immediate and significant cash value to our shareholders, while also allowing our shareholders to participate in the future upside of ELZONRIS's European launch."

Elcin Barker Ergun, CEO of Menarini Group, remarked, "Stemline is an excellent fit for Menarini, enabling us to expand our presence in the U.S. with an established biopharmaceutical company focused on developing oncology therapeutics. Through this acquisition, we will continue to strengthen our portfolio and pipeline of oncology assets and deliver novel therapies around the world."

The company described BPDCN, formerly blastic NK-cell lymphoma, as "an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes which typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera."

Stemline Therapeutics is a commercial-stage biopharmaceutical company headquartered in New York that develops and markets oncology therapeutics. The firm stated that its "ELZONRIS^® (tagraxofusp) is a targeted therapy directed to CD123 and is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN." Stemline noted that ELZONRIS is also being currently being evaluated in clinical studies for other indications including chronic myelomonocytic leukemia, myelofibrosis and acute myeloid leukemia.

The Menarini Group is an international pharmaceutical company based in Italy which operates and sells its products in more than 100 countries. The company stated that it has $4.2 billion in sales annually. The company's medicines address many areas of illnesses including cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic therapeutic areas and oncology.

Stemline Therapeutics began the day with a market capitalization of around $249.2 million with approximately 54.27 million shares outstanding and a short interest of about 11.3%. STML shares opened nearly 150% higher today at $11.81 (+$7.06, +148.63%) over Friday's closing price of $4.75. The stock has traded today between $1.81 and $12.35 per share and is currently trading at $12.10 (+$7.35, +154.74%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: STML:NASDAQ, )

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: Hydroxychloroquine as a game-changer Winning a Pulitzer A logical back to work metric Yearly flu death numbers aren’t real Remdesivir does NOT change survival rate The FBI’s reputation If you would like my channel to have a wider audience and higher production quality, please donate […]

The post Episode 955 Scott Adams: Extra Cussing Tonight. Put the Kids to Bed. Close Your Windows, Get Under the Covers appeared first on Scott Adams' Blog.

My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: Watching Anderson Cooper CNN is like being on mushrooms Why state governments are best for reopening decisions Disbanding the task force, it’s time Moonface Ben Shapiro’s clear description of coronavirus situation If you would like my channel to have a wider audience and higher production […]

The post Episode 957 Scott Adams: Let Me Tell You About the Psychedelic Mushroom I Accidentally Ingested Called CNN appeared first on Scott Adams' Blog.

My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: The coronavirus pandemic viewed through a Dilbert filter Victor David Hanson: “credentialed class” keeps getting it wrong My Twitter debate with a doctor, on testing feasibility Models function is to manipulate perception Paying to have airline middle seats empty If you would like my channel […]

The post Episode 958 Scott Adams: Grab Your Beverage and Buckle Up appeared first on Scott Adams' Blog.

My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: Adam Schiff lied for years…but broke no laws We do NOT know if Russia hacked DNC? Law enforcement targeted/framed President Trump to take him out “Cheryl The Server” theory applied to the lockdown If you would like to enjoy this same content plus bonus content […]

The post Episode 964 Scott Adams: Grab Your Beverage Because it’s Time For… appeared first on Scott Adams' Blog.

An international team of scientists has described a rare fossil site that is believed to be among the earliest evidence of different fish species using a common nursery -- much like ones utilized by some fish today.

read more

Soccer is an increasingly popular sport in the United States, both professionally and recreationally, with over 3 million registered soccer players under 19 years of age playing in leagues every year. A new study conducted by the Center for Injury Research and Policy of the Research Institute at Nationwide Children's Hospital found that with the increase in the number of players there has been a rise in the number and rate of injuries.

read more

What do you think of Science for Environment Policy? Tell us your thoughts with our online survey. The survey aims to assess how the service has diversified and responded to audience needs. Many thanks for your valuable feedback.

The challenge of measuring the ‘absence of waste’ makes it particularly difficult to monitor and evaluate waste prevention policies. Researchers have examined the strengths and weaknesses of nine methods of assessing waste prevention, and recommend a hybrid approach, which combines the best of many methods, as particularly valuable.

Sustainable urban waste management has progressed over recent decades, with recycling of waste becoming a routine activity across the EU. However, the increasing volume and complexity of waste poses ongoing challenges for policymakers and municipal administrators. New research suggests that a rethink around how household waste is sorted could lead to more resources being recovered from solid waste.

Death and mourning were largely considered private matters in the 20th century, with the public remembrances common in previous eras replaced by intimate gatherings behind closed doors in funeral parlors and family homes.

read more

Why do some people want to live a very long time, while others would prefer to die relatively young? In a latest study, a team of researchers including Vegard Skirbekk, PhD, at the Robert N. Butler Columbia Aging Center, investigated how long young and middle-aged adults in the United States say they want to live in relation to a number of personal characteristics. The results showed that more than one out of six people would prefer to die younger than age 80, before reaching average life expectancy. There was no indication that the relationship between preferring a life shorter or longer than average life expectancy depended on age, gender or education.

read more

A new study -- the first to look at social media's effect on memory -- suggests posting personal experiences on social media makes those events much easier to recall.

read more

Working together to create stronger results, that’s collaboration. It’s at the heart of every modern organisation, and one of the main ingredients for success. But how can you make the most of it in your business setting? Are your people equipped with the tools they need to truly thrive when they work together?

Travelling by coach or train has a lower impact on the climate than travelling by air or car, but using a small diesel car to carry several passengers can have similarly low impacts per person, new research suggests. Air travel is the worst form of transport, in terms of global warming impact, the researchers found, but the average percentage occupancy of a mode of transport significantly affects the impact per passenger.

It is better to put forward our views and deal with the multitude of possible outcomes than to ponder what if we had spoken.

Public support for pay-as-you-throw (PAYT) waste schemes is significantly higher among those who have actually experienced them, finds new research. The study indicates that there is less resistance to such schemes, which charge householders a fee that varies with the amount of waste collected, once they have been introduced.

The criminal minds too have evolved during this pandemic. While there has been a significant drop in number of heinous crimes in city, cybercrime cases have spiked since lockdown.

Cybersecurity researchers have accused Xiaomi of infringing on the privacy of its phone users by recording their 'private' web and phone use habits.

The benefit from big data only comes if you have knowledge of data capabilities and limitations.

Machines can protect systems in a way humans just can’t and, for that reason, advanced automation is going to be the way forward as companies look to protect their estates in a battle-ridden landscape.

How India Inc is navigating the challenges of taking production applications to the cloud.

Mercury contamination of some wild fish species in areas of the Czech Republic may put anglers’ health at risk, a new study suggests. The research showed that EU-wide and Czech national regulatory limits for mercury were exceeded in at least one analysed sample at 63% of the sites surveyed. However, contamination levels varied substantially between locations and species, the researchers say.

Do you find the Science for Environment Policy RSS feeds useful? Could they be improved? We would be grateful if you could spare a few moments to provide some feedback on the feeds with our short online survey for subscribers:http://www.surveymonkey.com/s/VMHTCLQ. Thank you for your time.

At BT Global Services connections are our business. We are trusted by thousands of enterprises around the world, combining our global strength in networks, IT and innovation with local presence, expertise and delivery. Watch this video to find out how we can help you connect for a better future.

Grey's productivity is being disrupted, Myke is giving in to the tropes of Youtube, and they both played PewDiePie's Tuber Simulator.

CBS San Antonio

A LARGE home that will comfortably accommodate even a big brood, this Lauderdale property has a lot going for it.

The Kings Langley Players continues its 95th anniversary celebrations with a popular black comedy.

A new app to show users if they've come into contact with someone with Covid-19 is being trialled this week.

CULPEPER — The Virginia Department of Transportation invites the public to attend an upcoming design public hearing on the proposed rehabilitation...